At a glance
ClinicalIndex Comparison RecordN/ACompleted· 15,000 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Personalized Antiplatelet Therapy According to CYP2C19 Genotype in Coronary Artery Disease: A Real World Study
In Brief
An observational study for Coronary Artery Disease. Completed, enrolled 15,000 participants.
Detailed Summary
This study is a prospective, no-randomized, single-center study performed on 15000 consecutive coronary artery patients from Dec. 2016 to Oct. 2021. All these patients were detected CYP2C19 genotype. The antiplatelet treatment was recorded according to the therapy actually adopted by the patients.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
Countries--
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartDec 2016
Primary CompletionJun 2021
Study CompletionOct 2021
First PostedDec 2021
TodayJul 2026
First PostedDec 30, 2021
Enrollment StartDec 1, 2016
Primary CompletionJun 1, 2021
Study CompletionOct 1, 2021
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 4.5 years ago